首页> 外国专利> BIOLOGICAL PACEMAKERS INCORPORATING HCN2 AND SKM1 GENES

BIOLOGICAL PACEMAKERS INCORPORATING HCN2 AND SKM1 GENES

机译:包含HCN2和SKM1基因的生物制药商

摘要

It is demonstrated that hyperpolarization-activated cyclic nucleotide-gated (HCN)-based biological pacing, especially that achieved by transduction of the HCN2 gene into cardiac cells in vivo, was significantly improved by co-transduction of the skeletal muscle sodium channel 1 (SkMI) gene. Expression of both genes hyperpolarized the action potential (AP) threshold. When viral biological pacemaker constructs carrying genes for HCN2 and SkMI were injected into the heart of dogs in vivo, the pacemaker function was facilitated by the slow depolarizing HCN2 current and the hyperpolarized AP threshold generated by SkMI. This dual gene therapy provided both highly efficient pacing and a brisk autonomic response that is superior to those of previously developed gene- or cell-based approaches.
机译:已证明,通过共转导骨骼肌钠通道1(SkMI),可以显着改善超极化激活的环状核苷酸门控(HCN)为基础的生物起搏,尤其是通过将HCN2基因体内转导进入心肌细胞而实现的生物起搏。 )基因。两个基因的表达使动作电位(AP)阈值超极化。当将带有HCN2和SkMI基因的病毒生物起搏器构建体体内注射到狗的心脏中时,起搏器功能会因缓慢的去极化HCN2电流和SkMI产生的超极化AP阈值而得到促进。这种双基因疗法提供了高效的起搏和轻快的自主反应,优于以前开发的基于基因或细胞的方法。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号